167 related articles for article (PubMed ID: 36175619)
1. Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel-Lindau gene in the ccRCC.
Chesnel F; Jullion E; Delalande O; Couturier A; Alusse A; Le Goff X; Lenglet M; Gardie B; Abadie C; Arlot-Bonnemains Y
Br J Cancer; 2022 Nov; 127(11):1954-1962. PubMed ID: 36175619
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response.
Desimone MC; Rathmell WK; Threadgill DW
J Natl Cancer Inst; 2013 Sep; 105(18):1355-64. PubMed ID: 23990666
[TBL] [Abstract][Full Text] [Related]
3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
4. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
5. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
Gossage L; Pires DE; Olivera-Nappa Á; Asenjo J; Bycroft M; Blundell TL; Eisen T
Hum Mol Genet; 2014 Nov; 23(22):5976-88. PubMed ID: 24969085
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family.
Yuan P; Sun Q; Liang H; Wang W; Li L; Wang Y; Deng H; Lai L; Chen X; Zhou X
Cancer Biol Ther; 2016 Jun; 17(6):599-603. PubMed ID: 27057652
[TBL] [Abstract][Full Text] [Related]
7. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
8. A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.
Cingoz S; van der Luijt RB; Kurt E; Apaydin M; Akkol I; Ozgen MH
Fam Cancer; 2013 Mar; 12(1):111-7. PubMed ID: 23224817
[TBL] [Abstract][Full Text] [Related]
9. Algorithmic assessment of missense mutation severity in the Von-Hippel Lindau protein.
Fields FR; Suresh N; Hiller M; Freed SD; Haldar K; Lee SW
PLoS One; 2020; 15(11):e0234100. PubMed ID: 33151962
[TBL] [Abstract][Full Text] [Related]
10. Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.
Guinot A; Lehmann H; Wild PJ; Frew IJ
J Pathol; 2016 Jul; 239(3):365-73. PubMed ID: 27126173
[TBL] [Abstract][Full Text] [Related]
11. VHL, the story of a tumour suppressor gene.
Gossage L; Eisen T; Maher ER
Nat Rev Cancer; 2015 Jan; 15(1):55-64. PubMed ID: 25533676
[TBL] [Abstract][Full Text] [Related]
12. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease.
Wittström E; Nordling M; Andréasson S
Ophthalmic Genet; 2014 Jun; 35(2):91-106. PubMed ID: 24555745
[TBL] [Abstract][Full Text] [Related]
14. Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the
Alosi D; Bisgaard ML; Hemmingsen SN; Krogh LN; Mikkelsen HB; Binderup MLM
Curr Genomics; 2017 Feb; 18(1):93-103. PubMed ID: 28503092
[TBL] [Abstract][Full Text] [Related]
15. Whole-Exome Sequencing Identifies the VHL Mutation (c.262T > C, p.Try88Arg) in Non-Obstructive Azoospermia-Associated Cystic Renal Cell Carcinoma.
Man Y; Shang X; Liu C; Zhang W; Huang Q; Ma S; Shiang R; Zhang F; Zhang L; Zhang Z
Curr Oncol; 2022 Mar; 29(4):2376-2384. PubMed ID: 35448166
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular features of familial and sporadic cases of von Hippel-Lindau disease from Mexico.
Chacon-Camacho OF; Rodriguez-Dennen F; Camacho-Molina A; Rasmussen A; Alonso-Vilatela E; Zenteno JC
Clin Exp Ophthalmol; 2010 Apr; 38(3):277-83. PubMed ID: 20447124
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
19. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
20. The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities.
Elias R; Zhang Q; Brugarolas J
Cancer J; 2020; 26(5):390-398. PubMed ID: 32947307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
